Variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnoea/hypopnoea syndrome (OSAHS)
| ISRCTN | ISRCTN43085025 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN43085025 |
| Secondary identifying numbers | 2005/R/SL/01 |
- Submission date
- 28/04/2009
- Registration date
- 11/05/2009
- Last edited
- 24/02/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Neil Douglas
Scientific
Scientific
Department of Respiratory Medicine
Second Floor
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh
EH16 4SA
United Kingdom
Study information
| Study design | Randomised double-blind (patients and researchers) cross-over single-centre trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Other |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Randomised controlled trial of variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnoea/hypopnoea syndrome (OSAHS) |
| Study objectives | Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a common illness affecting approx 4% of middle-aged men and 2% of middle aged women, who most frequently complain of symptoms of snoring and breathing pauses during sleep and daytime sleepiness. OSAHS is caused by relaxation of the upper airway during sleep, predisposing the airway to narrowing and eventual collapse. The restoration of airway patency is achieved by short arousals from sleep to allow breathing before sleep ensues again. The treatment of choice for OSAHS is continuous positive airway pressure (CPAP), which is a mechanical treatment involving the patient wearing a nasal mask during sleep, through which is blown a gentle airstream that splints the upper airway open, preventing collapse, breathing pauses, sleep disruption and dips in oxygenation. This randomised controlled cross-over trial will seek to determine whether OSAHS patients on variable-pressure CPAP (AutoSet Spirit™) for six weeks have better outcomes over fixed-pressure CPAP for: 1. Patients' treatment preference 2. Patient-orientated function on treatment (objective and subjective sleepiness, quality of life, vigilance, side-effects, symptoms) 3. Clinician-orientated treatment success (CPAP use, CPAP pressure, residual Apnoea-Hypopnea Index [AHI], mask leak) 4. Direct economic costs (staff and patient time, equipment costs) 5. Indirect economic benefits (health utility/quality-adjusted life years [QALYs]) |
| Ethics approval(s) | Lothian NHS Board, Lothian Local Research Ethics Committee 04, approved on 17 February 2005 (ref: 04/S1104/41) |
| Health condition(s) or problem(s) studied | Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) |
| Intervention | This is a randomised double-blind cross-over trial with 6 weeks of fixed-pressure continuous positive airways pressure (CPAP) and 6 weeks of variable-pressure CPAP. The first two weeks of each treatment was taken as a wash-out period. Eligible patients will be identified during the Dept of Sleep Medicine's weekly clinical review of cases, where full casenotes and investigations are available to ascertain inclusion and exclusion criteria. Consecutive eligible patients will be approached with information on the study and asked to consent to participation. Excluded or declining patients in the series will have reasons for these recorded for later post-hoc comparison with the recruited patient group. Consenting patients will receive CPAP education and mask-fitting as per our usual practice and automated CPAP titration using Spirit units, to determine therapeutic pressure for fixed-pressure CPAP (95th centile of pressure profile, unless adjusted by clinical staff for technical reasons). Patients will be asked to complete Epworth and SF-36® Health Survey just before titration, as a contemporaneous measure of pre-treatment status. After titration study, all patients will be issued with a Spirit unit set in the appropriate treatment mode (fixed- or variable-pressure CPAP) for home use over the first 6 week treatment limb. At the end of each 6 week treatment limb, patients are asked to attend with their Spirit CPAP units for a 3 hour session of testing, including breaks, and collecting the following measurements: 1. Objective sleepiness: Two 40-min Oxford Sleep Resistance (OSLER) tests (sleep resistance task) 2. Subjective sleepiness Epworth sleepiness scale 3. Vigilance Physiological vigilance test (PVT) 4. Symptom ratings Nocturnal and daytime symptoms 5. Health-related quality of life SF-36® Health Survey 6. CPAP side effects Edinburgh side-effects checklist 7. CPAP use and efficacy of Spirit CPAP units' memory (final 4 weeks): 7.1. CPAP use 7.2. CPAP pressure 7.3. Mask leak 7.4. Residual AHI on CPAP 8. At the last session patients will also be asked to rate treatment preference: variable-pressure or fixed-pressure CPAP |
| Intervention type | Other |
| Primary outcome measure | Patient preference, recorded once at trial end and assessed using a chi-square test. |
| Secondary outcome measures | 1. Patient-orientated effectiveness of treatment (sleepiness, symptoms, side-effects) 2. Physiologically-orientated effectiveness of CPAP (AHI, CPAP pressure, CPAP use) |
| Overall study start date | 14/03/2005 |
| Completion date | 31/12/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 200 |
| Key inclusion criteria | 1. Both males and females, between 18 and 70 years of age 2. CPAP naïve patients 3. Epworth Sleepiness Scale (ESS) >10 OR history of troublesome sleepiness when driving 4. AHI >15 on polysomnography or AHI/respiratory disturbance index (RDI) >25 on limited sleep study |
| Key exclusion criteria | 1. Severe neurological deficit sufficient to compromise CPAP usability or understanding 2. Significant co-morbidity (severe or unstable respiratory, neurological, metabolic or cardiac disease) 3. Co-existing sleep disorder such as narcolepsy, periodic limb movement syndrome 4. Contra-indications to CPAP use including recent pneumothorax |
| Date of first enrolment | 14/03/2005 |
| Date of final enrolment | 31/12/2008 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
Department of Respiratory Medicine
Edinburgh
EH16 4SA
United Kingdom
EH16 4SA
United Kingdom
Sponsor information
Lothian NHS Board (UK)
Hospital/treatment centre
Hospital/treatment centre
Lothian Local Research Committee 04
Deaconess House
148 Pleasance
Edinburgh
EH8 9RS
Scotland
United Kingdom
| Website | http://www.nhslothian.scot.nhs.uk/aboutus/ourorganisation/nhsboard/lhb.asp |
|---|---|
"ROR" |
https://ror.org/03q82t418 |
Funders
Funder type
Industry
ResMed Ltd (Australia) (ref: RESPMED052)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/02/2010 | Yes | No |
